anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
&lt;P&gt;PROBLEM TO BE SOLVED: To find an ingredient which promotes the production of decholin, to provide an external preparation for the skin, which exhibits excellent effects on preventing and improving ageing symptoms, and to provide a food.  &lt;P&gt;SOLUTION: This external preparation for the skin contains a Caulerpa racemosa extract and a Livistona R. Br. extract which have a decholin production-promoting action. The food contains the Caulerpa racemosa extract and the Livistona R. Br. extract which have the decholin production-promoting action.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a protein and nucleic acid useful for the study and/or production of vaccines.  &lt;P&gt;SOLUTION: Disclosed are proteins containing a specific amino acid sequence and derived from Neisseria gonorrhoeae, and a nucleic acid molecule encoding these proteins. These proteins are antigens useful for a vaccine, immunological composition and/or diagnostic agent. They are also useful for distinguishing between gonococcus and meningococcus and, in particular, between gonococcus and serogroup B meningococcus. The proteins are naturally prepared by various means such as recombinant expression, purification from Neisseria, and chemical synthesis in various forms such as natural products and fusion products. Preferably these are substantially prepared in a pure form.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Pro104) antibodies that bind to Pro 104 on a mammalian cell in vivo. The invention also encompasses compositions comprising an anti-Prol04 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Pro 104 antibody, as well as an expression vector comprising the isolated&#39;l nucleic acid. Also provided are cells that produce the anti-Pro 104 antibodies. The invention encompasses a method of producing the anti-Pro l04 antibodies. Other aspects of the invention are a method of killing a Pro 104-expressing cancer cell, comprising contacting the cancer cell with an antiProl04 antibody and a method of alleviating or treating a Pro 104-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Pro 104 antibody to the mammal.
PURPOSE:To obtain the titled composition effective for preventing various diseases of adult people and maintaining health, by decocting a plant seed or an embryo bud thereof, fermenting the decocted plant seed or embryo bud with a microorganism and adding a vegetable oil obtained from a decocted plant to the fermented material. CONSTITUTION:A plant seed or an embryo bud thereof is decocted, fermented with a microorganism and blended with a vegetable oil obtained from a decocted plant to give an active oxygen suppressive composition. The composition suppresses formation of excess active oxygen and peroxide lipid (active oxygen suppressive substance, etc., for short, including peroxide lipid) in human body, causing various diseases of adult people (e.g. arteriosclerosis, cerebral infarct, myocardial infarction, cancer, etc.), incurable diseases such as malignant rheumatoid arthritis, Behcet&#39; disease, etc., which are big problems in terms of health. In the production of the composition, uniform heating is carried out by far infrared rays, constant temperature bath, etc., not to inactivate the active oxygen suppressive substances, etc., by the decoction.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a biologically active substance having antiinflammatory effects with low toxity.  &lt;P&gt;SOLUTION: The extract of characteristic ingredient of Radix Stephaniae tetrandrae (SPRST) has the antiinflammatory effects. The antiinflammatory effects of the SPRST is the result of mutual action of Tetrandrine, Fangchinokine and other effective ingredients. The SPRST is a special extract of the Chinese medicine having antiinflammatory effects with low cytotoxicity. The SPRST carries out upregulation of calcium influx and generation of active oxygen (ROS) by G protein, and has the antiinflammatory effects and protective function to ishaemic-reperfusion injury by inhibiting occurrence of Mac-1 (CD11B/CD18) by up-regulation of heterophilic leucocyte.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
PURPOSE:The titled pharmaceutical containing a citrate as a stabilizer. CONSTITUTION:A kallikrein pharmaceutical obtained by incorporating preferably 0.1-10wt% citrate, e.g. sodium citrate, as a stabilizer in kallikrein. The resultant pharmaceutical is useful for treating not only peripheral blood vessels but also various dermatopathies, e.g. scleriasis, Raynaud&#39;s syndromes or phlebocholosis, considered due to quasiperipheral angiopathy, and effective for treating cerebral hypometabolism. The dosage form thereof includes injection, tablet, external agent, etc. The amount of the kallikrein to be incorporated in the external agent is preferably 1-1,000 kallikrein units/g. The kallikrein to be incorporated in the oral agent or injection is preferably human urinous kallikrein, and the dose thereof is preferably 1-100 kallikrein units/g.
The present invention features therapeutic bacteriophage deficient in the lysin protein (&#34;Lys minus&#34; phage). Lys minus bacteriophage are incapable of facilitating efficient lysis of the bacterial host since the enzymatic activity of the lysin of the phage is needed for breaking down the peptidoglycan layer of the bacterial cell wall. Lys minus bacteriophage retain activity in invasion of its appropriate bacterial host, destruction of the bacterial genome, and replication, which are sufficient to inhibit bacterial growth and replication. Therefore, the therapeutic Lys minus phage stops the spread of infection by the bacterial pathogen without lysis of the bacterium. This approach is attractive as it also prevents the release of the phage progeny, thus reducing or eliminating the potential for generation of immune responses against the phage. The incapacitated bacterial pathogen is then removed by the normal defense systems such as phagocytes and macrophages.
PROBLEM TO BE SOLVED: To obtain a cosmetic having light preventing effects, capable of effectively preventing especially UV light rays, by using both a specific triazine derivative and an emulsifying agent composed of a specific glyceryl compound. SOLUTION: 4,4&#39;,4&#34;-(1,3,5-Triazine-2,4,6-triyltriimino)-trisbenzoic acid tris(2- ethylhexyl ester) of formula I is combined with an emulsifying agent composed of a glyceryl compound of formula II (R1 to R3 are each H or a 8-24C fatty acid; (n) is 2-8) and used. The added amount of the composed of formula I is fairly increased by adding the emulsifying agent of formula II. The amount of the compound of formula I added is 0.1-10.0wt.%, especially about 0.5-6.0wt.% based on the total of the composition. The amount of the compound of formula II added is 0.01-250.0wt.%, especially about 0.5-6.0wt.%. The composition is further mixed with 4-isopropylbenzyl salicylate, 2-ethylhexyl salicylate (octyl salicylate), etc., to give a composition further acting as a light protecting filter.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a composition for ameliorating a bowel motion, containing a slightly assimilable saccharide.  &lt;P&gt;SOLUTION: The composition for ameliorating the bowel motion contains DFA (difructose anhydride) or melibiose. These two kinds of the saccharides have ameliorating effect on human defecation by direct drinking or taking these saccharides. An intake form is not especially required. The saccharide is directly dissolved in water as it is or processed into a food and taken. An ordinary food processing method is applied in the case of mixing the composition with a food. When these two kinds of saccharides are drunk, the saccharides are partially assimilated by enteric bacteria, especially a bifidobacterium or hardly assimilated, transferred to the blood and decomposed and metabolized in the liver.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
There is provided a wearable device and/or system for determining one or more of potential, imminent and actual touching of a user&#39;s face by the user&#39;s hand. The wearable device may comprise two sensors. The sensors may be configured to sense parameters indicative of the position and/or orientation of the user&#39;s arm, or part of the user&#39;s arm. A first sensor may be configured to sense an angle between the user&#39;s forearm and the user&#39;s upper arm. A second sensor may be configured to sense an orientation of the user&#39;s forearm with respect to gravity. The sensor signals may be sent to a processor for determining whether the user&#39;s arm position is indicative of face touching. The processor may be comprised as part of the wearable device, or the processor may comprised as part of the system separate to the wearable device, for example remote from the wearable device. The wearable device and/or system may comprise an output device for indicating that the user&#39;s arm position is indicative of face touching.
554,850. Toxins antitoxins &amp;c. TRIGGS, W. W. (Lederle Laboratories, Inc.). March 27, 1942, No. 4094. [Class 81 (i)] Pertussis (whooping-cough) toxin is obtained by culturing pertussis bacilli in a culture medium containing small amount of soluble starch and peptone, a stream of CO 2  gas being passed through the medium which is maintained at 32‹-37‹C, the culture continuing for 4 to 10 days and the toxin solution being separated by centrifuging and filtering. The culture medium preferably comprises a meat infusion. Toxoid is obtained from the toxin by heating at 40‹C with formaldehyde for a week. Antitoxin is obtained by injecting a rabbit with toxoid and optionally also with toxin and bleeding the animal after 7 days to obtain plasma. Specification 512,196 is referred to.
1,155,713. Polyhalopolyethers. L&#39;OREAL. 25 April, 1966 [23 April, 1965; 22 Nov., 1965; 6 April, 1966], No. 56132/67. Divided out of 1,155,712. Heading C2C. Mixtures of compounds of the general Formula (I) wherein R is a linear or branched aliphatic radical comprising a chain of 8-22 carbon atoms or is an alkylaryl radical comprising such a chain, X is a halogen atom and n has a statistical average value greater than 2 but not greater than 10, are prepared by polycondensing a glycerol epihalohydrin on to a compound ROH in a molar ratio of n :1 in the presence of a boron trifluoride or antimony pentachloride catalyst. The compounds of Formula (I) in which R is an aliphatic radical are claimed per se.
This invention relates to a biological process for the biosynthesis of two intracellular solutes identified as di-mannosyl-di-myo-inositol phosphates and 1,3&#39;-di-myo- inositol phosphate. These have been identified in the hypothermophilic bacteria Thermatoga maritima and Thermatoga neapolitana (growth Topt 80 degree C) during growth at supraoptimal temperatures in complex medium. The environmental conditions necessary for their accumulation in high concentrations indicate that these new compatible solutes can have an effect in protecting macromolecules (specifically biocatalysts) and cells against operations involving heating, drying or freezing. Di-mannosyl-di-myo-inositol phosphate and 1,3&#39;-di-myo- inositol phosphate can be used in enzyme catalysed processes at high temperatures or when these are performed in the presence of chemical denaturing agents such as detergents, organic solvents, oxidizing agents or caotropic agents such as urea or guanidine chloride with the intention of stabilizing their activity over the short and long term. Di-mannosyl-di-myo-inositol phosphate and 1,3&#39;-di-myo- inositol phosphate can also be used to stabilize liposomes and other membrane systems used in the microencapsulation of drugs and other compounds used in the pharmaceutical, cosmetics, detergents and other industries. &lt;IMAGE&gt; Di-mannosyl-di-myo-inositol phosphate and 1,3&#39;-di-myo- inositol phosphate can also be used during the drying of proteins and whole cells for transport and prolonged conservation and also as adjuvants for the preservation of microorganism strains or animal and plant cell lines, as well as perfused organs by freeze-drying or at low temperatures.
A coating composition for medicaments (see Group VI) comprises a film-forming substance having uniformly dispersed therein a finely-divided mineral solid which is inert to the film-forming substance and which is present in amount sufficient to prevent the film from cracking and crazing upon ageing, i.e. 10-150 per cent by weight based on the weight of the film-forming substance.  The film-forming substance may be a dicarboxylic acid ester of cellulose containing free carboxyl groups such as cellulose acetate phthalate and cellulose propionate phthalate, or a cellulose ether.  Specified mineral solids include talc, fuller&#39;s earth, diatomaceous earth, calamine, bentonite, pumice and insoluble sodium metaphosphate. Plasticizers, such as propylene glycol, triacetin, tripropionin, ethyl acid adipate and butyl acid phthalate, and edible surface-active agents, such as lecithin and sorbitan monooleate, may also be present.  In an example erythromycin tablets are coated with a composition comprising cellulose acetate phthalate. talc, anhydrous alcohol, anhydrous acetone, propylene glycol and sorbitan monooleate, Specification 526,276,[Group IV], is referred to.ALSO:An enteric coating composition comprises an enteric film-forming substance having uniformly dispersed therein a finely divided mineral solid which is inert to the film-forming substance and which is present in an amount sufficient to prevent the film from cracking and crazing upon ageing, i.e. 10-150 per cent by weight based on the weight of the film-forming substance. The film-forming substance may be a dicarboxylic acid ester of cellulose containing free carboxyl groups such as cellulose acetate phthalate and cellulose propionate phthalate, polyvinyl acetate, polyvinylphthalate, a cellulose ether, a copolymer of an aliphatic dibasic unsaturated acid and a vinyl compound, shellac, zein, balsam tolu or a higher fatty acid. Specified mineral solids include talc, fuller&#39;s earth, diatomaceous earth, calamine, bentonite, pumice and insoluble sodium metaphosphate. Plasticizers, such as propylene glycol, triacetin, tripropionin, ethyl acid adipate and butyl acid phthalate and edible surface active agents such as lecithin and sorbitan monooleate may also be present.  Medicaments which may be coated include antibiotics such as erythromycin, ammonium chloride, sodium salicylate, diethylstilboestrol, gentian violet, barbiturates; anti-epileptics, acriflavine and ferrous sulphate.  These materials may be coated by known methods.  In an example erythromycin tablets are coated with a composition comprising cellulose acetate phthalate, talc, anhydrous alcohol anhydrous acetone, propylene glycol and sorbitan mono-oleate. Specification 526,276 is referred to.
PROBLEM TO BE SOLVED: To obtain a composition intended for cosmetics or the dermatological field by providing a liquid lipid phase coupled with a specific particle-contg. solid phase so as to be stabilized and/or homogenized. SOLUTION: This composition is obtained by providing a liquid lipid phase coupled with a solid phase containing particles of (A) a partially or wholly crosslinked elastomeric organopolysiloxane so that the solid phase account for &gt;=10 wt.% of the lipid phase and also by including spherical organic particles each &lt;=10 (pref. &lt;=5) μm in size (e.g. microbeads of methysilsesquioxane resin). It is preferable that the component A is produced by addition and crosslinking reaction between (1) an organopolysiloxane having two or more lower alkenyl groups per molecule and (2) an organopolysiloxane having two or more H atoms bound to Si atom per molecule in the presence of a platinum-type catalyst.
Nowadays shopping in supermarkets, malls, marts and other commercial places becomes a very important part of human life. Apart from just shopping, these places offer so many entertainment platforms for every age group of people under one roof. Therefore, to attract the customers, the shop owners are always trying to introduce unique flavour in their shopping platforms, such as: Digital Payment methods, Automatic controlling systems, location indicator of the particular store, Smart Trolley and etc. Shopping Trolley is always hidden but a very crucial part of your shopping. Here, we are putting this hidden component into the central attraction for the shopping. In our proposed invention idea (Smart Trolley), we are planning to put so many customer friendly features into the trolley, which takes the customer&#39;s shopping experience into another level. In our proposed Smart Trolley system, we are planning to incorporate smart lock, smart pooling, product scanners, location indicator, weighing machine, e-payment system and product reminder/assistant. In the Covid-19 pandemic, technology has played a very important role in the smooth run of human life and it has also convinced the young as well as old people to make their life align with the recent advancements. With this emphasis, our invention, “Smart Trolley” will give the smart, safe and secure shopping experience to the customers as well as store owners too. Business retail&#39;s owners can also adapt the proposed system in their business platforms because the implementing cost will also be adjusted in the long run as the proposed system will help to reduce the supporting staff size.
The invention relates to an azo-benzoic acid type compound. The compound has a structure shown by a formula (1). The invention also provides a preparation method of the compound with the structure shown by the formula (1). The invention also provides an application of the azo-benzoic acid type compound or a pharmaceutically acceptable salt and a medicine complex thereof in serving as an agonist for a G-protein coupled receptor 35. The invention also provides an application of the azo-benzoic acid type compound or the pharmaceutically acceptable salt and the medicine complex thereof in preparation of medicines for preventing and/or treating inflammation, asthma, Parkinson&#39;s disease, angiocardiopathy and intestinal cancer. The azo-benzoic acid type compound provided by the invention has a relatively high targeting property for the G-protein coupled receptor 35.
Methods of forming multi-lamellar microcapsules having alternating layers of hydrophilic and hydrophobic immiscible liquid phases have been developed using different polymer/solvent systems. The methods use liquid-liquid diffusion and simultaneous lateral phase separation, controlled by proper timed-sequence exposures of immiscible phases and low shear mixing, to form narrow size distributions of spherical, multilamellar microcapsules. The use of special formulations of solubilized drugs, surfactants, and polymeric co-surfactants in aqueous vehicles which are dispersed in hydrocarbon solvents containing small quantities of oil, low molecular weight co-surfactants and glycerides that are aqueous insoluble enables the formation of unique microcapsules which can carry large amounts of pharmaceuticals in both aqueous and non-aqueous solvent compartments. The liquid microcapsules are quickly formed in a single step and can include a polymeric outer &#34;skin&#34; which protects the microcapsules during physical manipulation or exposure to high shear forces. Water-in-oil and oil-in-water microcapsules have been formed both in 1×g and in microgravity, which contain several types of drugs co-encapsulated within different fluid compartments inside the same microcapsule. Large, spherical multi-lamellar microcapsules have been formed including a cytotoxic drug co-encapsulated with a radiocontrast medium which has advantages for chemoembolization of vascular tumors. In certain cases, crystals of the drug form inside the microcapsules providing zero-order and first order, sustained drug release kinetics.
NEW MATERIAL:A compound expressed by formula I (R is H or methyl; n is 5-20). EXAMPLE:10-Mercaptodecyl methacrylate. USE:An undercoating agent for bonding metallic materials, having excellent adhesive force with improved water resistance to constituent component noble metals of a polymerization curing type adhesive and especially suitable for dental uses. PREPARATION:An omega-hydroxyalkyl (meth)acrylate is reacted with an aromatic or aliphatic sulfonyl chloride, preferably p-toluenesulfonyl chloride, etc., to provide a sulfonate expressed by formula II (R1 is H or methyl; R2 is hydrocarbon), which is then reacted with thiourea to afford a compound expressed by formula III (Y&lt;1&gt; is sulfonium or halogen ion). If metallic ions are present in the reaction system, mercaptide ions are generated to instantly link to the metallic ions to precipitate the compound expressed by formula III as a salt. An acid is then added to the salt to provide the aimed compound expressed by formula I.
An immune-peroxidase test for serologic diagnostics of porcine circovirus includes inoculation of the cells of sensitive culture to 96-well plastic microplates with flat bottom; dilution of test serums by the method of two-fold dilution with addition of working dilution of circovirus type 2 in the 96-well plastic microplates with round bottom with following contact of those and with bringing to the wells of the microplate with mono-layer of cell culture; incubation during seven days under conditions of COincubator; removal from the microplate wells of the culture medium, with washing the cell mono-layer; introduction of fixing buffer to all the microplate wells; step-by-step introduction to all the microplate wells – working dilution of specific blood serum, working dilution of conjugate, solution of substrate; termination of reaction through adding stop-solution to each well of the table and registration of reaction under inverted light microscope based on the principle of presence or absence of specific dyeing of the cells – infected cells look like single cells or groups of cells (plaques) with cytoplasm dyed to dark-red color and light nucleus. The test is used for reveal of specific humoral antibodies against the circovirus type 2 in domestic and wild hog through investigation of biological material (serum of blood, milk, colostrums); for cultivation sensitive to circovirus type 2 cell cultures (SK-6, RPK-15, PSGK) are used; grown in cultural vessels (glass or plastic pads) cell monolayer is taken by means of solution of trypsin-versen at ratio of 1:9. For cultivation of cell culture, 7-10 % of embryo blood serum of cattle is added to nutrient media; the test blood serums before investigation undergo inactivation at temperature during 30 minutes with titration with the method of double dilution with adding working dilution 1000 U of circovirus type 2 (reference - &#34; Stoon 1010&#34; or deposited strains) with exposition during one hour at +. Introduction of content to the cells of the plate with sensitive cell culture is performed at partial formation of mono-layer of those (50 %) with addition of 2 % embryo serum of cattle blood. The reference or deposited strains of circovirus type 2 are used as control virus. At fixation of mono-layer of cells 96 % ethyl alcohol is used. Porcine specific blood serum against the circovirus type 2 is used as working dilution of positive serum. The Tween-20 is not used while monolayer washing. At termination of reaction - NaCL; all manipulations with drying the cell monolayer are carried out under conditions of thermostat at temperature and exposition – one hour. When recording the reaction the presence of plaque – absence of antibodies, and the absence of plaque – presence of anti-bodies against circovirus type 2 in porcine blood serum are taken into account:.